Maxim Pharmaceuticals, Myriad Genetics deal

MAXM received a $1 million milestone under a 2003 deal in which MYGN licensed rights to MAXM's MPC-6827 apoptosis-inducing cancer compound (see BioCentury, Dec. 8, 2003). The payment was triggered by...